Designing a Tetravalent mRNA Vaccine for Scarlet Fever: Integrating Machine Learning and Reverse Vaccinology
Preprint
- 23 December 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Scarlet fever, commonly referred to as sandpaper rash, is a prevalent infection caused by the bacterium Streptococcus pyogenes, which is part of the Group A Streptococcus (GAS) family of gram-positive cocci. This infection affects both adults and children worldwide. This study focused on designing a tetravalent modified nucleotide mRNA vaccine using machine learning and reverse vaccinology techniques. The vaccine development focuses on three critical proteins: C5a peptidase, M protein, and streptolysin O. These proteins play significant roles in the pathogenesis of Streptococcus pyogenes and are key targets for inducing a robust immune response. Methods:. Our study involved extensive profiling for potential vaccine targets, which included three types of epitopes, namely B-cell, CTL, and HTL. The process we undertook in the choice of these epitopes was based on a range of significant criteria such as the ones with high antigenicity that ensure the immune system is able to recognize and respond to the vaccine; the ones with low toxicity that would be used to reduce the side effects, and those of no allergenicity to avoid cases of allergic reactions among vaccinated individuals. To further evaluate the interactions between the identified T-cell epitopes and their corresponding human leukocyte antigen (HLA) alleles, we employed molecular docking studies. Results: The results indicated promising binding affinities, suggesting that these epitopes are likely to elicit strong T-cell responses.Notably, the docking analysis revealed a binding energy of -818.5 kcal/mol for the peptide NTTNRHYSL with HLA-B08:01, and -776.5 kcal/mol for RTYPAALQL with HLA-A32:01. These studies provided insights into how well the epitopes bind to specific HLA molecules, which is vital for T-cell recognition and activation. Conclusion: These two peptides, exhibiting optimal binding affinity and stability, are promising candidates for advancing the development of next-generation mRNA vaccines. Further validation will be conducted through in vitro analyses to confirm their ability to elicit an immune response.Keywords
All Related Versions
This publication has 25 references indexed in Scilit:
- mRNA vaccines for infectious diseases — advances, challenges and opportunitiesNature Reviews Drug Discovery, 2024
- Update on the development of Group A Streptococcus vaccinesnpj Vaccines, 2023
- Exploring Highly Antigenic Protein of Campylobacter jejuni for Designing Epitope Based Vaccine: Immunoinformatics ApproachInternational Journal of Peptide Research and Therapeutics, 2018
- Impact of meteorological factors on scarlet fever in Jiangsu province, ChinaPublic Health, 2018
- Streptococcal M proteins and their role as virulence determinantsClinica Chimica Acta, 2010
- The global burden of group A streptococcal diseasesThe Lancet Infectious Diseases, 2005
- Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranesImmunology, 2001
- Verification of protein structures: Patterns of nonbonded atomic interactionsProtein Science, 1993
- Complete nucleotide sequence of the streptococcal C5a peptidase gene of Streptococcus pyogenes.Journal of Biological Chemistry, 1990
- THE ANTIGENIC COMPLEX OF STREPTOCOCCUS HÆMOLYTICUSJournal of Experimental Medicine, 1928